Alliance Study Shows Promising Results For Patients with Advanced Neuroendocrine Tumors

The Alliance for Clinical Trials in Oncology today announced that an independent Data and Safety Monitoring Board (DSMB) determined that the phase III CABINET (A021602) pivotal trial met its primary endpoint at an interim analysis in both of the trial’s cohorts, demonstrating statistically significant and clinically meaningful improvements in progression-free survival (PFS). CABINET is evaluating cabozantinib compared with placebo in patients with either advanced pancreatic neuroendocri


2023 Fall Hybrid Group Meeting
- November 1-4, 2023 | Register | Schedule

2024 Spring Hybrid Group Meeting
- May 15-18, 2024

2024 Fall Hybrid Group Meeting
- October 30-November 2, 2024

All meetings are open to all
Alliance members.